Search

Gilead Sciences Inc.

Затворен

СекторЗдравеопазване

134.39 -1.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

134.01

Максимум

134.82

Ключови измерители

By Trading Economics

Приходи

-162M

2B

Продажби

-965M

7B

P/E

Средно за сектора

17.664

60.149

EPS

2.03

Дивидентна доходност

2.37

Марж на печалбата

29.037

Служители

17,000

EBITDA

1.2B

3.5B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+19.53% upside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

2.37%

2.24%

Следващи печалби

6.08.2026 г.

Следваща дата на дивидент

28.09.2026 г.

Следваща дата на екс-дивидент

14.09.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3.5B

161B

Предишно отваряне

135.84

Предишно затваряне

134.39

Настроения в новините

By Acuity

37%

63%

97 / 340 Класиране в Healthcare

Gilead Sciences Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.07.2026 г., 19:56 ч. UTC

News

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

16.07.2026 г., 23:41 ч. UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

15.07.2026 г., 18:46 ч. UTC

Gilead Sciences Inc shares are higher, reflecting positive momentum in biotechnology amid a declining U.S. Dollar and easing inflation concerns.

14.07.2026 г., 23:16 ч. UTC

Gilead Sciences shares are higher in after-market trading, following a steady increase from earlier lows amid softer inflation data and a rally in Treasury bonds.

13.07.2026 г., 17:26 ч. UTC

News

Gilead Sciences is gaining as it prepares for key product launches in 2026, including Bulevirtide and a new HIV regimen under FDA review.

10.07.2026 г., 20:01 ч. UTC

News

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

9.07.2026 г., 19:36 ч. UTC

News

Gilead Sciences Inc's shares are lower despite regulatory achievements for Trodelvy and advancements in its HIV pipeline, reflecting broader market volatility.

8.07.2026 г., 23:51 ч. UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

7.07.2026 г., 23:02 ч. UTC

Gilead Sciences Inc. shares are lower in after-market hours, reflecting broader market declines amid rising geopolitical tensions and a widening U.S. trade deficit.

6.07.2026 г., 20:02 ч. UTC

News
Social Media

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2.07.2026 г., 22:56 ч. UTC

Gilead Sciences shares traded lower in after-market hours, with no specific news identified. Broader market mixed amid weaker U.S. jobless data.

1.07.2026 г., 19:14 ч. UTC

Gilead Sciences Inc. shares are lower today, reflecting routine performance within their one-month trading range despite stability around the midpoint.

30.06.2026 г., 20:07 ч. UTC

Social Media

A social media post suggests bullish sentiment around Gilead Sciences, as a fund buys March call options. Shares are trading roughly flat in the session.

29.06.2026 г., 23:06 ч. UTC

Gilead Sciences Inc. shares are trading lower in after-market hours. Investor focus remains on upcoming U.S.-Iran talks that may impact market sentiment.

26.06.2026 г., 22:11 ч. UTC

Gilead Sciences Inc shares are lower in after-market hours, driven by notable declines in the Biotechnology sub-sector. No specific company news was identified.

25.06.2026 г., 23:56 ч. UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.

24.06.2026 г., 23:36 ч. UTC

News

Gilead Sciences' Trodelvy receives FDA approval for first-line treatment of triple-negative breast cancer, boosting shares in after-market hours.

23.06.2026 г., 23:56 ч. UTC

Event

European Commission approves Gilead's Trodelvy for triple-negative breast cancer, boosting shares higher in after-market hours amid notable intraday fluctuations.

22.06.2026 г., 23:02 ч. UTC

Gilead Sciences Inc shares are lower in after-market hours, reversing earlier gains and settling near the lower end of their one-month trading range.

18.06.2026 г., 23:06 ч. UTC

Gilead Sciences shares are lower in after-market trading, reflecting a decline since Thursday's close and nearing the lower end of their one-month range.

17.06.2026 г., 23:16 ч. UTC

Gilead Sciences Inc. shares are lower in after-market hours, with notable volatility earlier in the session. No specific news was identified to explain the decline.

16.06.2026 г., 23:36 ч. UTC

Gilead Sciences Inc. shares gained slightly in after-market trading, fluctuating within a narrow range amid limited volatility and no specific company news.

15.06.2026 г., 21:11 ч. UTC

News

Gilead Sciences' supplemental New Drug Application for Yeztugo accepted by the FDA. Shares are lower in after-market trading despite the regulatory milestone.

12.06.2026 г., 23:01 ч. UTC

Gilead Sciences Inc. shares are higher in after-market trading, gaining slightly since Friday's close despite mixed broader market sentiment.

11.06.2026 г., 23:02 ч. UTC

News

Gilead Sciences reported positive results from two Phase 3 trials for an HIV treatment. Shares are higher in after-market hours following a session pullback.

10.06.2026 г., 23:11 ч. UTC

Gilead Sciences shares rose in after-market trading, driven by a strong Biotechnology sub-sector trend. The stock remains below its 20-day moving average.

9.06.2026 г., 23:21 ч. UTC

Gilead Sciences Inc shares are higher in after-market trading, rebounding from earlier losses despite remaining below the 20-day moving average.

8.06.2026 г., 23:26 ч. UTC

News

Gilead Sciences Inc. shares declined in after-market trading following the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for Trodelvy and Keytruda.

5.06.2026 г., 23:46 ч. UTC

Gilead Sciences shares declined in after-market trading amid broader market pressures from strong U.S. job growth raising interest rate concerns.

4.06.2026 г., 19:46 ч. UTC

Social Media

Gilead Sciences is gaining amid social media discussions on its strategic positioning and attention at Goldman Sachs' healthcare conference.

Сравнение с други в отрасъла

Ценова промяна

Gilead Sciences Inc. Прогноза

Ценова цел

By TipRanks

19.53% нагоре

12-месечна прогноза

Среден 160.5 USD  19.53%

Висок 180 USD

Нисък 120 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Gilead Sciences Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

18

Купи

3

Задържане

0

Продай

Настроение

By Acuity

97 / 340 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
help-icon Live chat